With further research of RIKEN's stem cells:
1. The recent monkey-to-monkey trials did not use their "allogeneic iPSC-retinal pigment epithelial cells". And they plan to use these allogeneic cells in their next trial.
2. Major concerns about potential immunogenecity (immune rejection) of their type of stem cells have been raised by their peers.
(http://stemcellassays.com/2015/09/first-ips-cell-clinical-trial-insights/)
Either way, RIKEN in their next clinical trial with the use of their "allogeneic stem cells" are also in a fight to prove whether their iPS cell bank are truly useful/valid or not.
http://www.riken.jp/en/pr/press/2016/20160916_2/
riken temcell, page-24
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27654 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 4500 | 1 |
View Market Depth
| Last trade - 16.12pm 16/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable